EUMEDICA
ActiveSummary
EUMEDICA has been active since 1951 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €26.3m and a net result of €7.2m. Equity is growing by about 9.6% per year across the filed financial years. Its solvency ranks better than 47% of 6,142 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
Directors
Board 3
Day-to-day management 3
Permanent representatives 1
Statutory auditor 1
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
- Statutory auditor
- began earlier
| Name | Functions and periods |
|---|---|
| INVESTPHAR HOLDING LUXEMBOURG SA |
|
| Denis Pichel |
|
| Sébastien Van de Velde |
|
| BMS & C° |
|
| Béatrice OLIVIER |
|
Owners and capital
Owners
1 ownerChain of control
- INVESTPHAR HOLDING LUXEMBOURG S.A.LU
- EUMEDICA
Highest known parent: INVESTPHAR HOLDING LUXEMBOURG S.A. (Luxembourg). The sources do not say who stands above it.
Owners 1
- INVESTPHAR HOLDING LUXEMBOURG S.A.LUconsolidating parentconsolidates
Sources: the companies' annual accounts, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Capital and shareholders
- Bournonville Pharma 2 shares · BEF 2,000
- Unipebe 3,865 shares · BEF 3,865,000
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.
- 03-11-2025 Capital increase of BEF 1,665,000 · to BEF 4,665,000 · 333 new shares · in cash
- 03-11-2025 Capital increase of BEF 2,660,000 · to BEF 7,320,000 · 532 new shares · in cash
- 03-11-2025 Capital increase of BEF 2,000 · to BEF 7,327,000 · 2 new shares · “attribution aux actionnaires de Bournonville Pharma en rémunération de l’apport à titre d’absorption du patrimoine de cette société”
- 03-11-2025 Capital increase of BEF 3,865,000 · to BEF 11,192,000 · 3,865 new shares · “attribution aux associés de Unipebe en rémunération de l’apport à titre d’absorption du patrimoine de cette société”
- 03-11-2025 Capital reduction of BEF 5,515,000 · to BEF 5,677,000 · “annulation de cinq mille cinq cent quinze actions dont la société était devenue propriétaire”, “y compris toutes les actions assorties du privilège mentionné au cinquième alinéa ci-avant”
- 03-11-2025 Capital increase of BEF 2,323,000 · to BEF 8,000,000 · no new shares · from reserves
- 03-11-2025 Capital increase of BEF 8,000,000 · to BEF 16,000,000 · 14,538 new shares · in kind
- 03-11-2025 Capital conversion · €133,833.70
Show 1 older capital entries
- 03-11-2025 Capital increase of €204,512.16 · to €734,975.50 · 1,076 new shares · “création de mille septante-six nouvelles actions sans désignation de valeur nominale”